Cover Image
市場調查報告書

全球免疫毒素癌症治療藥市場、臨床實驗平台分析

Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020

出版商 KuicK Research 商品編碼 364457
出版日期 內容資訊 英文 240 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球免疫毒素癌症治療藥市場、臨床實驗平台分析 Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020
出版日期: 2016年07月22日 內容資訊: 英文 240 Pages
簡介

本報告提供全球免疫毒素癌症治療藥市場相關調查分析、概要、優點、應用、未來預測、臨床實驗平台、前臨床階段的產品等系統性資訊。

第1章 所謂免疫毒素

第2章 免疫毒素

第3章 毒素源

  • 植物毒素
  • 細菌毒素

第4章 免疫毒素的生產

第5章 免疫毒素的種類

  • 炭疽為基礎的毒素
  • 白喉毒素 (DT),DT衍生物
  • 綠色膿菌外毒素 (PE),PE衍生物
  • 核糖體惰性化蛋白質為基礎的免疫毒素
  • 核糖核酸酶基礎的免疫毒素等

第6章 免疫毒素癌症治療分析

  • 骨髓惡性腫瘤
  • 固體癌

第7章 免疫毒素的優點

第8章 免疫毒素的應用

  • 固體癌
  • 白血病等

第9章 全球免疫毒素癌症治療藥市場預測

  • 目前市場方案
  • 全球免疫毒素癌症治療藥臨床實驗平台概要

第10章 全球免疫毒素癌症治療藥市場動態

  • 可喜的市場參數
  • 商業化的課題

第11章 全球免疫毒素癌症治療藥市場未來發展預測

第12章 全球免疫毒素癌症治療藥的臨床實驗平台:各企業,各適應症,各相位

  • 研究階段
  • 前臨床階段
  • 第一階段
  • 第一階段/第二階段
  • 第二階段
  • 第二階段/第三階段
  • 第三階段

第13章 開發中止/未報告的免疫毒素癌症治療藥的臨床實驗平台:各企業,各適應症,各相位

  • 沒有開發報告
  • 中止
  • 中斷

第14章 競爭情形

  • AbbVie
  • AbGenomics
  • Agensys
  • Ambrx
  • Amgen
  • AREVA Med
  • Bayer HealthCare
  • Biotest
  • Celldex Therapeutics
  • CuraGen Corporation
  • Genentech
  • Genmab
  • Heidelberg Pharma
  • ImmunoGen
  • Neurocrine Biosciences
  • Research Corporation Technologies
  • Sanofi
  • Seattle Genetics
  • Sorrento Therapeutics
  • Spirogen

圖表

目錄

Immunotoxins are new generation chemotherapeutic agents innovated to include the specificity of monoclonal antibody and cytotoxicity of toxins extracted from plant or bacterial source. The targeting moiety carries the specificity of the antibody and is directed to the target where it either binds to the cell surface antigen, receptor or the ligand of the targeted disease. Cytotoxicity is mediated by the protein toxins, which maybe protein at times.

The cytotoxic part may comprise of any molecule which has the capability to induce cell death either by interfering with the cell machinery, modifying cell membrane, or by induction of apoptotic pathways. The cytotoxicity thus successfully delivered either to cytoplasm or the ribosomes of the target cell may be lethal to the cell.

During its ignition era, immunotoxins basically comprised of monoclonal antibodies (MAb) or growth factors chemically conjugated to protein toxins by the formation of the disulphide bonds. These molecules contained full length protein toxins are were not that cell specific. With progress in the research and technology, second generation immunotoxins made an entry. They were modulated in a way to remove the toxin mediated cell binding and spare the normal cells from cytotoxicity. The immunotoxins of this generation contained full length Immunoglobulin (IgG) bound to the toxic moiety.

The entry of third generation was marked by coming of recombinant technology which was targeted to remove the immunogenicity by shifting from murine origin immunoglobulins to humanized recombinant IgGs. The molecules of this generation thus formed consisted of fragments of variable domain (Fv) conjugated to IgG. Thus, created immunotoxins had excellent activity, specificity, better penetration and less immunogenicity.

Immunotoxins continue to be actively investigated as viable alternatives to conventional therapies for a variety of diseases. An array of different recombinant, antibody formats are now available for use in immunotoxins. While these design changes have improved the overall in vitro and preclinical in vivo efficacy of immunotoxins, increased potency does not address either of the two major concerns for drugs of this type: immunogenicity and toxicity.

In the past three to four decades, a wide variety of immunotoxins have been tested against a wide variety of malignancies in cell culture, in animal models, and in patients. The most useful of these agents appear to be the relatively small recombinant fusion toxins that contain either growth factor or Fv fragments as ligands. The most sensitive diseases appear to be hematologic malignancies. Future development will need to address combinations of immunotoxins with other anticancer therapies in order to overcome problems of tumor penetration, toxicity, and immunogenicity.

After many years of pre-clinical development, there has been a recent burst in the number of clinical trials using antibodies or antibody fragments to target potent cytotoxic molecules to cancer cells. Several of these trials have shown impressive clinical responses indicating that we are at the beginning of a new and exciting phase of cancer treatment. Additional studies are now required to define the optimal dose, schedule, and combinations for specific malignancies. Also several problems have been identified. One of these is immunogenicity, which may be solved by removing B and T cell epitopes. Another is likely to be drug and toxin resistance. Never the less we expect this new approach is likely to have a major impact in cancer treatment.

“Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020” Report Highlights:

  • Introduction to Immunotoxins
  • Cancer Immunotoxins Therapy Analysis
  • Advantages of Immunotoxins upon other Anticancerous Drugs
  • Applications of Immunotoxins to Multiple Cancer Therapies
  • Global Cancer Immunotoxins Market Future Prospects
  • Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase
  • Global Cancer Immunotoxins Clinical Pipeline: 52 Cancer Immunotoxins
  • Majority Cancer Immunotoxins in Preclinical Phase: 21 Drugs

Table of Contents

1. Introduction to Immunotoxins

2. Immunotoxins: The Three Generations & Advancements

3. Sources of Toxins

  • 3.1. Plant Toxins
  • 3.2. Bacterial Toxins

4. Production of Immunotoxins

5. Types of Immunotoxins

  • 5.1. Anthrax Based Toxins
  • 5.2. Diphtheria Toxin (DT) & DT Derivatives
  • 5.3. Pseudomonas Exotoxin (PE) & PE Derivatives
  • 5.4. Ribosome Inactivating Proteins Based Immunotoxins
    • 5.4.1. Ricin
    • 5.4.2. Saporin based Immunotoxins
    • 5.4.3. Recombinant Constructs of RIP I Toxins
  • 5.5. Ribonucleases based Immunotoxins
  • 5.6. Proapoptotic Proteins as Targeted Immunotoxins

6. Cancer Immunotoxins Therapy Analysis

  • 6.1. Immunotoxins for Hematologic Malignancies
    • 6.1.1. Denileukin Diftitox (ONTAK, DAB389IL-2)
    • 6.1.2. LMB-2(anti-Tac[Fv]-PE38)
    • 6.1.3. Moxetumomab Pasudotox
    • 6.1.4. A-dmDT390-bisFv (UCHT1)
    • 6.1.5. DT2219ARL
    • 6.1.6. HuM195-Gelonin
  • 6.2. Immunotoxins for Solid Tumors
    • 6.2.1. SS1P
    • 6.2.2. RG7787
    • 6.2.3. Oportuzumab Monatox
    • 6.2.4. VB6-845
    • 6.2.5. D2C7-(scdsFv)-PE38KDEL

7. Advantages of Immunotoxins upon other Anticancerous Drugs

8. Applications of Immunotoxins

  • 8.1. Immunotoxins against Solid Tumors
    • 8.1.1. Immunotoxin against Colon Carcinoma
    • 8.1.2. Immunotoxin against Breast Cancer & Sarcoma
    • 8.1.3. Immunotoxin against Glioma & Head & Neck Squamous Cell Carcinoma
    • 8.1.4. Immunotoxin against Prostate & Lung Cancer
  • 8.2. Immunotoxins against Leukemias
  • 8.3. Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs

9. Global Cancer Immunotoxins Market Outlook

  • 9.1. Current Market Scenario
  • 9.2. Cancer Immunotoxins Clinical Pipeline Overview

10. Global Cancer Immunotoxins Market Dynamics

  • 10.1. Favorable Parameters
    • 10.1.1. Large Segment of Patient Still Devoid of Appropriate Medication
    • 10.1.2. Cancer: A Severe Pathological Condition
    • 10.1.3. Unmet Requirement of Completely Curative Agents
    • 10.1.4. Unwanted Effects of the Existing Drugs
  • 10.2. Commercialization Challenges
    • 10.2.1. Stern Regulatory Guidelines: A Major Hurdle
    • 10.2.2. Never Ending Phase of Research & Development
    • 10.2.3. Conduction of Clinical Trials
    • 10.2.4. Funding Research & Development: A Super Costly Affair
    • 10.2.5. Immunogenicity of Immunotoxins

11. Global Cancer Immunotoxins Market Future Prospects

12. Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase

  • 12.1. Research
  • 12.2. Preclinical
  • 12.3. Phase-I
  • 12.4. Phase-I/II
  • 12.5. Phase-II
  • 12.6. Phase-II/III
  • 12.7. Phase-III

13. Discontinued & No Development in Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase

  • 13.1. No Development Reported
  • 13.2. Discontinued
  • 13.3. Suspended

14. Competitive Landscape

  • 14.1. AbbVie
  • 14.2. AbGenomics
  • 14.3. Agensys
  • 14.4. Ambrx
  • 14.5. Amgen
  • 14.6. AREVA Med
  • 14.7. Bayer HealthCare
  • 14.8. Biotest
  • 14.9. Celldex Therapeutics
  • 14.10. CuraGen Corporation
  • 14.11. Genentech
  • 14.12. Genmab
  • 14.13. Heidelberg Pharma
  • 14.14. ImmunoGen
  • 14.15. Neurocrine Biosciences
  • 14.16. Research Corporation Technologies
  • 14.17. Sanofi
  • 14.18. Seattle Genetics
  • 14.19. Sorrento Therapeutics
  • 14.20. Spirogen

>List of Tables

  • Table 5-1: Immunotoxins in Clinical Development using Diphtheria as a Toxin Moiety
  • Table 5-2: Clinically evaluated/under evaluation PE-based Immunotoxins against Hematologic Malignancies
  • Table 5-3: Clinically evaluated/under evaluation PE-based Immunotoxins against Solid Tumors
  • Table 5-4: Clinical Trials in Patients with Saporin Containing Immunotoxins
  • Table 6-1: Immunotoxins for Leukemia

List of Figures

  • Figure 2-1: Immunotoxins & Their Recombinant Forms
  • Figure 3-1: Sources of Toxins
  • Figure 4-1: Steps Involved in Production of Immunotoxins
  • Figure 5-1: Different Types of Immunotoxins
  • Figure 5-2: Mechanism of Action of Anthrax Based Immunotoxins
  • Figure 5-3: Composition of the Diphtheria Derived Toxins
  • Figure 5-4: Steps Involved in Apoptosis by Diphtheria Derived Immunotoxins
  • Figure 5-5: Domains of PE with Their Specificities
  • Figure 5-6: Mode of Apoptosis Taken by Pseudomonas Exotoxin (PE) & PE Derivatives
  • Figure 6-1: Major Targets of Immunotoxins as Anticancer Agents
  • Figure 6-2: Some of Important Immunotoxins Targeting Hematological Malignancies
  • Figure 6-3: Some of Important Immunotoxins Targeting Solid Tumors
  • Figure 8-1: Major Applications of Immunotoxins
  • Figure 9-1: Cancer Immunotoxins Pipeline by Phase (%), 2016
  • Figure 9-2: Cancer Immunotoxins Pipeline by Phase (Numbers), 2016
  • Figure 9-3: Cancer Immunotoxins Pipeline by Phase (%), 2016
  • Figure 9-4: Cancer Immunotoxins Pipeline by Phase (Numbers), 2016
  • Figure 10-1: Favorable Parameters for Global Cancer Immunotoxins Market
  • Figure 10-2: Commercialization Challenges for Global Cancer Immunotoxins Market
  • Figure 14-1: AbGenomics - Clinical Pipeline
  • Figure 14-2: Amgen - Clinical Pipeline
  • Figure 14-3: Biotest - Clinical Pipeline
  • Figure 14-4: Genmab - Clinical Pipeline
  • Figure 14-50: Genmab - Clinical Pipeline
  • Figure 14-6: Neurocrine Biosciences - Clinical Pipeline
  • Figure 14-7: Sorrento Therapeutics - Clinical Pipeline
Back to Top